KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EPS (Weighted Average and Diluted) (2018 - 2025)

Historic EPS (Weighted Average and Diluted) for NovoCure (NVCR) over the last 8 years, with Q3 2025 value amounting to -$0.33.

  • NovoCure's EPS (Weighted Average and Diluted) fell 1785.71% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.61, marking a year-over-year decrease of 1582.73%. This contributed to the annual value of -$1.56 for FY2024, which is 2000.0% up from last year.
  • NovoCure's EPS (Weighted Average and Diluted) amounted to -$0.33 in Q3 2025, which was down 1785.71% from -$0.36 recorded in Q2 2025.
  • Over the past 5 years, NovoCure's EPS (Weighted Average and Diluted) peaked at -$0.04 during Q1 2021, and registered a low of -$0.61 during Q4 2024.
  • For the 5-year period, NovoCure's EPS (Weighted Average and Diluted) averaged around -$0.31, with its median value being -$0.31 (2024).
  • In the last 5 years, NovoCure's EPS (Weighted Average and Diluted) crashed by 115000.0% in 2023 and then skyrocketed by 4259.26% in 2024.
  • NovoCure's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.26 in 2021, then tumbled by 39.34% to -$0.36 in 2022, then decreased by 23.45% to -$0.44 in 2023, then crashed by 38.64% to -$0.61 in 2024, then surged by 45.9% to -$0.33 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.33 for Q3 2025, versus -$0.36 for Q2 2025 and -$0.31 for Q1 2025.